Trial to Evaluate the Safety and Tolerability of Repeated Intravitreal Injection of IBI302 in Neovascular AMD Patients
Status:
Completed
Trial end date:
2021-05-08
Target enrollment:
Participant gender:
Summary
This study is designed for multi-center, open-label, randomized, dose escalation phase I
trial to evaluate the safety and tolerability of a multiple dose intravitreal injection of
IBI302 in neovascular AMD patients.